MCT1 and MCT4 Review Separates Lactate Dependence From Mere Transporter Expression
- The review covers the proton-coupled transport mechanism, substrate recognition and chaperone-dependent trafficking of MCT1 and MCT4, and their distinct roles in tumor metabolic compartmentalization.
- It asks which cancers actually depend on lactate transport rather than just express the transporters.
- Inhibitors are grouped as nonselective, MCT1-selective, MCT4-selective or dual, and judged on potency, selectivity and translational evidence.
💡 Points Based on the abstract
The useful distinction is expression versus functional dependence, because that decides patient selection. MCT1 inhibitors alone tend to be rescued by MCT4 upregulation, so dual inhibition or biomarker-defined MCT4-low tumors is the sensible design. I'd also watch the safety side: MCT1 sits in heart, muscle and the retina, and an exposure that blocks tumor lactate flux may hit normal tissue.
📄 Paper · Biochemical Pharmacology ↗ Monocarboxylate transporters 1 and 4 in tumor lactate exchange: Molecular mechanisms, pharmacological inhibition, and therapeutic translation